Search

Your search keyword '"Schreiber, S"' showing total 5,081 results

Search Constraints

Start Over You searched for: Author "Schreiber, S" Remove constraint Author: "Schreiber, S"
5,081 results on '"Schreiber, S"'

Search Results

1. Two-color operation of a soft x-ray FEL with alternation of undulator tunes

2. Recovery time of a plasma-wakefield accelerator

3. POS0377 ASSOCIATION OF COMORBIDITIES, MICROBIOTA AND METABOLOMICS WITH ESTABLISHED AND DEVELOPING RHEUMATOID ARTHRITIS

4. AB1443 CONSISTENT SAFETY PROFILE OF SECUKINUMAB IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS: UPDATE ON THE DATA FROM POOLED CLINICAL TRIALS

5. BOPfox program for tight-binding and analytic bond-order potential calculations

6. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus

7. Recovery time of a plasma-wakefield accelerator

8. Navigating the multifaceted intricacies of the Na+-Cl− cotransporter, a highly regulated key effector in the control of hydromineral homeostasis.

9. First operation of a harmonic lasing self-seeded free electron laser

10. Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP)

11. X-Ray Science at DESY: Upgrade Programs for the User Facilities FLASH and PETRA III

16. DOP64 Steroid-sparing effect of risankizumab vs ustekinumab in patients with moderately to severely active Crohn’s Disease: Post hoc results from the phase 3b SEQUENCE trial

17. P144 Modulation of Immunometabolism via NLRX1 or PLXDC2: Novel Bimodal Mechanisms for the Treatment of Inflammatory Bowel Diseases

18. OP09 Oral ritlecitinib and brepocitinib in patients with moderate to severe active Crohn’s Disease: Data from the PIZZICATO umbrella study

19. P593 Efficacy of Risankizumab in Patients With Moderately to Severely Active Ulcerative Colitis by Prior Advanced Therapy Failure and Mechanism of Action: Post Hoc Analysis of the INSPIRE and COMMAND Phase 3 Studies

20. P792 Real-world evidence comparison of the effectiveness of ustekinumab with anti-TNF or vedolizumab in ulcerative colitis: 1-year maintenance therapy results from the prospective, observational RUN-UC study

22. OP06 Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study

23. P224 JAK-STAT-Driven Tryptophan Degradation Fuels Mucosal Inflammation through QPRT Suppression-Induced Quinolinic Acid Overflow

25. N02 Inflammatory bowel disease patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomized controlled trial in Germany (IBDBIO-ASSIST study) - The IBD nurses perspective

26. DOP70 Prevalence and severity of bowel urgency in Crohn’s Disease: Results from the Communicating Needs and Features of IBD Experience (CONFIDE) Survey

28. P902 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: 2 years results of the LIBERTY-CD study

31. DOP10 Risankizumab Versus Ustekinumab for the Achievement of Endoscopic Outcomes in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE Trial

32. P957 Subcutaneous infliximab (CT-P13 SC) for ulcerative colitis: 2-year extension results of the LIBERTY-UC study

33. OP03 Efficacy and safety of the oral selective sphingosine-1-phosphate-1 receptor modulator VTX002 in moderately to severely active Ulcerative Colitis: results from a randomised, double-blind, placebo-controlled, phase 2 trial

34. P678 Long-term efficacy, safety and health-related quality of life in patients who achieved comprehensive disease control with filgotinib in SELECTION: analysis of ~3 years in SELECTIONLTE

35. P983 Treatment of patients with moderate-to-severe Crohn’s disease with subcutaneous infliximab leads to an endoscopic response across all segments of the colon and terminal ileum: A post hoc analysis of the LIBERTY-CD study

36. DOP78 Efficacy of ozanimod by patient response trajectory subgroups identified using group-based trajectory modelling: a post hoc analysis of the phase 3 True North study

38. P285 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: European and US Patient and Health Care Professional Perspectives on the Broad Impact of Bowel Urgency in Ulcerative colitis

40. The FLASHForward Facility at DESY

41. Laser Wire Scanner Compton Scattering Techniques for the Measurement of the Transverse Beam Size of Particle Beams at Future Linear Colliders

42. Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2).

44. The FLASHForward facility at DESY

45. Experimental demonstration of novel beam characterization using a polarizable X-band transverse deflection structure

46. Ageing & Sports

49. Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn’s disease patients with secondary loss of response during ustekinumab maintenance therapy: week 16 results from the phase 3b POWER trial

50. Microbiome modification and improvement of signs and symptoms of COVID-19: Ileocolonic-release nicotinamide in a prospective, double-blind, randomized, placebo-controlled trial

Catalog

Books, media, physical & digital resources